Get the Stockscreener App
0.6424
8.53%
0.0505
After Hours:
.67
0.0276
+4.30%
Humacyte Inc stock is traded at $0.6424, with a volume of 4.71M.
It is up +8.53% in the last 24 hours and down -42.64% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$0.5919
Open:
$0.5813
24h Volume:
4.71M
Relative Volume:
0.69
Market Cap:
$142.63M
Revenue:
$2.04M
Net Income/Loss:
$-43.21M
P/E Ratio:
-3.1079
EPS:
-0.2067
Net Cash Flow:
$-105.93M
1W Performance:
-17.47%
1M Performance:
-42.64%
6M Performance:
-64.11%
1Y Performance:
-56.00%
1-Day Range:
$0.575
$0.6575
1-Week Range:
$0.5469
$0.7699
52-Week Range:
$0.5469
$2.93
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.6424 | 131.41M | 2.04M | -43.21M | -105.93M | -0.2067 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Why BTIG cut its target on Humacyte (HUMA) but kept a bullish view on the bigger opportunity - MSN
HC Wainwright Issues Positive Forecast for Humacyte Earnings - MarketBeat
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte, Inc. (HUMA) Shares Decline Despite Overall Market Rise: The Reason Explained - Bitget
HUMA: Benchmark Downgrades Humacyte with Lowered Price Target | - GuruFocus
Benchmark Reaffirms "Speculative Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Benchmark Downgrades Humacyte to Speculative Buy From Buy, Adjusts Price Target to $1 From $11 - moomoo.com
Earnings Miss: Can Humacyte Inc sustain its profitabilityPortfolio Growth Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Macro: Does Humacyte Inc Equity Warrant have declining or rising EPS2026 PreEarnings & Weekly Watchlist of Top Performers - baoquankhu1.vn
Piper Sandler Cuts Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat
Piper Sandler cuts Humacyte stock price target on weak sales - Investing.com UK
Piper Sandler cuts Humacyte stock price target on weak sales By Investing.com - Investing.com Canada
TD Cowen Has Lowered Expectations for Humacyte (NASDAQ:HUMA) Stock Price - MarketBeat
TD Cowen lowers Humacyte stock price target to $1 on launch concerns - investing.com
Piper Sandler Maintains Humacyte(HUMA.US) With Hold Rating, Cuts Target Price to $1 - moomoo.com
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Cuts Target Price to $1 - moomoo.com
Humacyte, Inc. (HUMA) reports Q4 loss, misses revenue estimates - MSN
Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger Opportunity - Yahoo Finance
Smart Money: Does Humacyte Inc Equity Warrant have declining or rising EPSPortfolio Update Summary & Stock Market Timing Techniques - baoquankhu1.vn
5 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
Humacyte earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Humacyte misses revenue target despite in-line earnings By Investing.com - ca.investing.com
Humacyte 10-K: Revenue $2.04M, EPS $(0.26) - TradingView
Humacyte (NASDAQ: HUMA) details Symvess FDA approval, launch and ATEV pipeline in 10-K - Stock Titan
Humacyte secures $1.48M Symvess purchase commitment in Saudi Arabia - MSN
Humacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral Capital - MarketBeat
Humacyte shares see BTIG price target cut to $3 on lower sales outlook - Investing.com UK
Humacyte shares see BTIG price target cut to $3 on lower sales outlook By Investing.com - Investing.com India
Humacyte (NASDAQ:HUMA) Issues Earnings Results - MarketBeat
BTIG Research Lowers Humacyte (NASDAQ:HUMA) Price Target to $3.00 - MarketBeat
Humacyte Q4 2025 earnings preview - MSN
Humacyte Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Humacyte Q4 2025 revenue misses forecast By Investing.com - Investing.com Australia
Earnings call transcript: Humacyte Q4 2025 revenue misses forecast - investing.com
HUMA: Symvess adoption grows with strong clinical data, improved pricing, and expanding global reach - TradingView
Humacyte Inc reports results for the quarter ended December 31Earnings Summary - tradingview.com
Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Humacyte earnings matched, revenue fell short of estimates - Investing.com
Humacyte misses revenue target despite in-line earnings - investing.com
Humacyte posts bigger-than-expected Q4 loss - TradingView
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - marketscreener.com
BRIEF-Humacyte Q4 Basic EPS USD -0.13 - TradingView
HUMA Should I Buy - Intellectia AI
Dip Buying: Can Humacyte Inc deliver consistent EPS growth2026 Big Picture & Growth Focused Investment Plans - baoquankhu1.vn
Humacyte, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Humacyte, Inc. (HUMA) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development - Bitget
Humacyte appoints Rick McElheny as SVP of business development - investing.com
Humacyte appoints Rick McElheny as SVP of business development By Investing.com - Investing.com Canada
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):